

7:55 AM	Welcome & Introduction <i>Renu Virmani, MD</i>	9:25 AM	Panel Discussion: What is the Target for Diagnosis and Therapy <i>Moderator: R. L. Wilensky</i> <i>Panelists: J. F. Granada, A. Lerman, P. R. Moreno, J. E. Muller, R. Virmani</i>
<i>New Insights into the Pathophysiology of Vulnerable Plaque and the Vulnerable Patient</i> <i>Moderators: Robert L. Wilensky, MD and Renu Virmani, MD</i>		<i>Detection of VP and the 'At-Risk' Patient: Noninvasive Testing and Biomarkers</i> <i>Moderators: Amir Lerman, MD and James E. Muller, MD</i>	
8:00 AM	Lipid Pool, Necrotic Core and Fibrous Cap Thickness <i>Renu Virmani, MD</i>	9:45 AM	Is CIMT an Effective Surrogate for Use in the Evaluation as Well as Approval of New Drugs for the Treatment of Cardiovascular Disease? <i>Allen J. Taylor, MD</i>
8:15 AM	Neovascularization and Intraplaque Hemorrhage <i>Pedro R. Moreno, MD</i>	9:55 AM	Molecular Targeting: A Potential Non-Invasive Strategy for Identifying Patients for Aggressive Therapy Methods <i>Stephen E. Epstein, MD</i>
8:25 AM	Role of the Vasa Vasorum in Plaque Progression <i>Amir Lerman, MD</i>	10:05 AM	Biomarkers to Predict Future Major Cardiovascular Events in High Risk Patients and the General Population <i>Robert S. Schwartz, MD</i>
8:35 AM	Atherothrombosis and the Immune System <i>Robert L. Wilensky, MD</i>	10:15 AM	The Future of Imaging as a Surrogate in the Development of New Cardiovascular Drugs <i>Steven E. Nissen, MD</i>
8:45 AM	Role of Progenitor Cells in Vascular Injury <i>Amir Lerman, MD</i>	10:25 AM	Panel Discussion: What Future Role Will Noninvasive Imaging Play in the Detection of Vulnerable Plaque? <i>Panelists: S. E. Epstein, A. Lerman, J. E. Muller, S. E. Nissen, R. S. Schwartz, A. J. Taylor</i>
8:55 AM	Lipid-Rich Plaques: Substrate for Spontaneous Thrombus or Thrombus <i>James E. Muller, MD</i>	10:40 AM	Break
9:05 AM	Animal Models to Study Vulnerable Plaque: The Inherited Familial Hypercholesterolemia Swine <i>Juan F. Granada, MD</i>		
9:15 AM	Membrane Red Blood Cell: Extravasation Leading to Progression of Atherothrombosis <i>Renu Virmani, MD</i>		

Detection of VP and the 'At-Risk'

Patient: Invasive Testing for

Morphologic Plaque Characterization

Moderators: Gary S. Mintz, MD and Sergio Waxman, MD

- 10:55 AM OCT and Vasa Vasorum Imaging
Gary S. Mintz, MD
- 11:05 AM Clinical Update & New Potential Applications for Virtual Histology
Paulina Margolis, MD, PhD
- 11:15 AM The ACS Patient: Will the Intracoronary Identification of the Lipid Filled Vulnerable Plaque Change the Therapy of High Risk Patient?
James E. Muller, MD
- 11:25 AM Prospective Early Identification of High-Risk Coronary Artery Vulnerable Plaque Based on in-vivo Assessment of Endothelial Shear Stress and Wall Morphology in Man: The PREDICTION Trial
Peter H. Stone, MD
- 11:35 AM Quantitative Colorimetry Applied to Angioscopy for Detection of High-Risk Plaque: New Light on an Old Technique
Sergio Waxman, MD
- 11:45 AM Panel Discussion
Moderators: G. S. Mintz, S. Waxman
Panelists: P. Margolis, J. E. Muller, P. H. Stone

12:05 PM Lunch & Visit the Exhibits

Studies in the Invasive Detection of Vulnerable Plaque

Moderator: Pedro R. Moreno, MD

- 1:15 PM The SECRET Trial
Patrick W. Serruys, MD, PhD
- 1:25 PM The IBIS-2 Trial: Role of Darapladib, a Selective Inhibitor of Lp-PLA2, to Reduce Cardiovascular Risk
Patrick W. Serruys, MD, PhD

The Future of HDL Therapy

Moderators: H. Bryan Brewer, Jr., MD and Steven E. Nissen, MD

- 1:35 PM Will the Development of New Niacin Formulations with Reduced Flushing Change the Treatment of the Dyslipoproteinemic Patient?
Yale B. Mitchell, MD
- 1:45 PM The Future of HDL Therapy in the Treatment of the High Risk Patient with Cardiovascular Disease
Ernst J. Schaefer, MD
- 1:55 PM Final Results from the Delipidation of HDL for Acute Coronary Syndrome Study
Ron Waksman, MD
- 2:05 PM HDL Mimetic Therapy in the Treatment of the Acute Coronary Syndrome Patient
H. Bryan Brewer, Jr., MD
- 2:15 PM The Future of the Next Generation of CETP Inhibitors to Raise HDL in the Treatment of Patients at High Risk for Cardiovascular Disease
Richard C. Pasternak, MD
- 2:25 PM Selective Increase in ApoA-I Synthesis: A Novel Approach to Increase HDL in High Risk Patients
Norman C.W. Wong, MD
- 2:35 PM What Do the Results of the JUPITER Trial Mean to the Practicing Cardiologist?
Judith Hsia, MD
- 2:45 PM What Should be the Requirements for Future Approval of New Drugs for Treatment of Cardiovascular Disease in High and Low Risk Patients?
Steven E. Nissen, MD

2:55 PM	Panel Discussion <i>Moderator: S. E. Nissen</i> <i>Panelists: H. B. Brewer, Jr., J. Hsia, E. J. Schaefer, R. Waksman, R. L. Wilensky, N. C.W. Wong</i>	4:05 PM	Why are Triglycerides an Independent Risk Factor for Cardiovascular Disease? <i>Frank M. Sacks, MD</i>
3:10 PM	Break	4:15 PM	Should the Cardiologist Treat the Patient with Metabolic Syndrome to Prevent Cardiovascular Disease? <i>Neil J. Stone, MD</i>
Non HDL Lipid Lowering Therapies <i>Moderator: Wm. James Howard, MD</i>		4:25 PM	Apolipoproteins vs Lipids as Indices of Coronary Risk and as Targets for Drug Treatment <i>Allan D. Sniderman, MD</i>
3:25 PM	What is the Optimal LDL Lowering Therapy for the Acute Coronary Syndrome Patient? <i>Wm. James Howard, MD</i>	4:35 PM	Updating the Cardiovascular Benefits of n-3 Fatty Acids <i>William S. Harris, PhD</i>
3:35 PM	What is the Optimal Lipid Therapy for the Diabetic Patient to Prevent Cardiovascular Disease? <i>Michael H. Davidson, MD</i>	4:45 PM	Panel Discussion <i>Moderator: W. J. Howard</i> <i>Panelists: M. H. Davidson, W. S. Harris, W. J. Howard, P. Kwiterovich, F. M. Sacks, A. D. Sniderman, N. J. Stone</i>
3:45 PM	Will the IMPROVE IT Trial Establish a New Target Value and Safety Profile for LDL-C Reduction for the Cardiovascular Field? <i>Thomas A. Musliner, MD</i>	5:15 PM	Adjourn
3:55 PM	What is the Value of LDL and HDL Subclasses in the Selection of Drugs in the Treatment of Cardiovascular Disease? <i>Peter Kwiterovich, MD</i>		